Evaluation of Clinical Outcomes According to HER2 Detection by Fluorescence In Situ Hybridization in Women with Metastatic Breast Cancer Treated with Trastuzumab

This publication has 33 references indexed in Scilit:

• Docetaxel Combined With Trastuzumab Is an Active Regimen in HER-2 3+ Overexpressing and Fluorescent In Situ Hybridization–Positive Metastatic Breast Cancer: A Multi-Institutional Phase II Trial
  Journal of Clinical Oncology, 2004
• Testing for HER-2/ neu in Breast Cancer: Is Fluorescence In Situ Hybridization Superior in Predicting Outcome?
  Advances in Anatomic Pathology, 2002
• Evaluation of HER-2/neu Gene Amplification and Overexpression: Comparison of Frequently Used Assay Methods in a Molecularly Characterized Cohort of Breast Cancer Specimens
  Journal of Clinical Oncology, 2002
• neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group.
  Journal of Clinical Oncology, 1998
• HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas.
  Journal of Clinical Oncology, 1997
• Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group.
  Journal of Clinical Oncology, 1992
• ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization.
  Proceedings of the National Academy of Sciences, 1992
• Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
  Science, 1989
• Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/neuOncogene
  Science, 1987
• Nonparametric Estimation from Incomplete Observations
  Journal of the American Statistical Association, 1958